The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- Congo-Kinshasa: Ebola Crisis-The Vaccines Debateon August 16, 2019 at 4:36 am
As I write this piece, the Democratic Republic of Congo (DRC) is reeling from an Ebola crisis with the World Health Organization (WHO) having declared it a global health emergency. It is reported ...
- Burundi starts Ebola vaccines for health workers: WHOon August 14, 2019 at 10:00 am
NAIROBI (Reuters) - Burundi has started vaccinating its health workers against Ebola, beginning with those near the border with the Democratic Republic of Congo, the World Health Organization (WHO) ...
- Behind the Life-saving Ebola Vaccine is a Story of Missed Opportunityon August 13, 2019 at 12:55 pm
In April 2005, Canadian microbiologist Steven Jones walked into an isolation ward clad in protective gear, picked up a chubby, burbling baby boy and fed him a bottle. Jones had arrived in Angola the ...
- Deploying Experimental Vaccines Against Ebolaon August 9, 2019 at 6:42 am
The current outbreak of Ebola in the Democratic Republic of Congo is the worst since the 2014-2016 epidemic in West Africa. More than 2,500 people have been infected, and 1,800 people have died. In ...
- Researchers in Uganda Start 2-Year Ebola Vaccine Trialon August 7, 2019 at 11:03 am
MBARARA, UGANDA - Eight hundred health workers involved in the fight against the Ebola virus are receiving doses of a two-part vaccine. Researchers who launched a trial this week for a new Ebola ...
- The Uganda vaccine trial: how African researchers are tackling Ebolaon August 7, 2019 at 2:36 am
Yap Boum is the regional representative for Epicenter Africa, the research arm of Médecins sans Frontières. He is involved in the Ebola outbreak and the use of the Ebola vaccine for MSF/Epicenter.
- GSK ends development of Ebola vaccine, hands work to U.S. instituteon August 6, 2019 at 5:20 am
LONDON, Aug 6 (Reuters) - British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak ...
- Sabin Institute acquires rights to develop vaccines for Ebola and Marburg viruseson August 6, 2019 at 4:19 am
The nonprofit Sabin Vaccine Institute is taking over development of vaccines to protect against two species of Ebola and a related virus, Marburg, acquiring the rights from GSK, the two entities ...
- The Sabine Vaccine Institute ; GSK: GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccineon August 6, 2019 at 4:09 am
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- GSK and the Sabin Vaccine ...
- GSK hands work on potential Ebola vaccines to U.S. instituteon August 6, 2019 at 4:05 am
LONDON (Reuters) - British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak ...
via Google News and Bing News